DOXORUBICIN (ADRIAMYCIN®) is an
anthracycline antibiotic which has been playing a significant and increasingly important role in the treatment of cancer. However, because of a cardiomyopathy which it causes with increasing frequency at high cumulative doses, it has been necessary to limit the total amount of doxorubicin to 550 mg/M2. The clinical utility of the agent would probably increase if this toxicity could be prevented or reduced without alteration of chemotherapeutic activity. Recently, Herman and colleagues have reported that ICRF-187, the (+ )-isomer of ICRF-159 [(± )-1,-2-bis (3,5,dioxopiperazinyl-1-yl) propane], reduced cardiac damage in doxorubicintreated dogs and daunomycin-treated rabbits . The present studies were carried out to determine whether ICRF-187 affords any protection against the histological lesions caused by doxorubicin in the mouse heart. Studies were also conducted using guinea pigs to determine if ICRF-187 would reduce a functional effect of doxorubicin administration, namely a reduced chronotropic response of the right atrium to histamine in vitro.
METHODS
Mouse study.-Female Cox ICR mice were obtained from Laboratory Animal Supply, Indianapolis, Ind., U.S.A. The animals Nere held in quarantine for 7 days and weighed 18-22 g at the start of the study. Purina Rodent Chow and water were permitted ad libitumn throughout the study.
The experimental design was essentially as described by Bertazzoli et al. (1979) with the exception that the animals were injected i.p. with ICRF-187 (50 mg/kg) or saline (10 ml/kg) 30 min before receiving doxorubicin hydrochloride (4 mg/kg) or saline (10 ml/kg) i.v. Group 1 animals received saline i.p. and saline i.v., Group 2 saline i.p. and doxorubicin i.v., and Group 3 ICRF-187 i.p. and doxorubicin i.v. The animals were injected on Tuesday and Friday of Weeks 1, 2, 5, 6 and 7, and killed by ether asphyxiation during week 11 of the study. Hearts and kidneys were taken at necropsy and fixed in 10%0 buffered formalin. Routine paraffin sections (3 ,um) of these organs were stained with haematoxylin and eosin and examined microscopically for damage. Severity of myocardial damage was graded as follows: Grade 1-very slighlt; scattered, single myocardial fibres w%xith vacuolation or degenerative changes. Grade 2-slight; scattered small groups of 
RESULTS

Mouse study
Results of the histological evaluation of heart and kidney sections are summarized in Table I . Control animals had no histological evidence of myocardial damage. In contrast, focal myocardial damage was found in 8/15 (53%) mice treated with doxorubicin (4 mg/kg x 10). Six mice had Grade 1 (very slight) and 2 had Grade 2 (slight) myocardial damage. Focal mononuclear cellular infiltration was found in 2 of the 8 doxorubicin damaged hearts. ICRF-187 (50 mg/kg, i.p.), administered before each of the 10 doses of doxorubicin, significantly reduced the incidence of doxorubicin-induced myocardial damage (P<0-05). Only 3/17 (18%) of the mice treated with ICRF-187 and doxorubicin had Grade 1 myocardial lesions.
The incidence of microscopic renal damage was similar for each treatment group, being 10, 13, and 6% in the control, salinedoxorubicin, and ICRF-187-doxorubicin groups respectively. Mice in both the saline-doxorubicin (28-6 + 3-4g; x + s.d.) and the ICRF-187-doxorubicin (28-1 + 2-7 g) groups weighed significantly less (P < 0-01) than the control (34.5 + 5.4 g) animals at the end of the experiment. The only animal *to die during the experiment, an animal in the ICRF-187-doxorubicin group, died 3 days after receiving the fourth pair of injections.
Guinea-pig studies
Results of an initial experiment to determine the effect of weekly i.p. administration of doxorubicin on the rate of contraction and response to histamine of atria mounted in vitro are summarized in Table II indicating that ICRF-187, the more watersoluble (+) isomer of ICRF-159, reduces myocardial histological damage induced t Significantly less than control, P < 0-05. t Significantly less than control, P < 0-01. § Bath concentration of histamine dihydrochloride, 3-64 x 10-6 mol/l.
by the chronic administration of anthracyclines in animals. ICRF-187 significantly reduced the incidence of doxorubicin-induced histological cardiac damage in mice when administered i.p. 30 min before doxorubicin. The dose of ICRF-187 used was 12X5 times the dose of doxorubicin, as it was in the dog study reported by . It is not known whether this is the optimum ratio of ICRF-187 to doxorubicin. The inability to completely block the cardiotoxic response to doxorubicin suggests that higher doses of ICRF-187 should be examined. Also, the possibility exists that doxorubicin has other cardiac effects which result in focal or diffuse vacuolar degeneration of myocardial fibres which are not affected by Doxorubicin alters the electrical as well as the contractile activity of the heart in animals and man, and can cause congestive heart failure (Ghione, 1978; Lenaz & Page, 1976) . Recent data, in addition to our results, suggest that one way of detecting functional myocardial effects of doxorubicin is by stimulation of the heart. Papish et al. (1981) found that evaluation of left ventricular function in the presence of a modest increase in systolic blood pressure induced by i.v. methoxamine can unmask abnormalities in doxorubicintreated patients with normal resting left ventricular function. They reported that 50% of the patients receiving mg/M2 doxorubicin had reduced left ventricular function when stressed. Breed et al. (1979) , working in vitro with electrically stimulated perfused hearts taken from doxorubicin-treated rats, found a dose-related decrease in maximal apico-basal shortening, no increase in shortening being observed after 12 weeks of treatment. Data from our guinea-pig experiments indicate that it is possible to detect a functional effect of doxorubicin on atrial myocardium before histological damage is evident. Chronic i.p. administration of doxorubicin (2 mg/kg weekly for 2 weeks or 1 mg/kg weekly for 3 weeks) caused a significant decrease in the in vitro chronotropic response of right atria to histamine. In guinea pigs treated weekly with 1 mg/kg, basal atrial rate was not altered and no histological myocardial damage was observed.
To our knowledge, ICRF-187 has not been tested to determine if it will block or reduce an effect of doxorubicin on cardiac function. Data reported here indicate that ICRF-187 will not block the effect of doxorubicin on the chronotropic response of right atria to histamine. The significance of this observation, and why this effect of chronic doxorubicin administration, unlike histological myocardial damage, was not reduced by ICRF-187, remain to be investigated.
Doxorubicin has been shown to have 2 distinctly different effects on cultured rat imyocardial cells, namely (1) nucleolar fragmentation, segregation and chromatin clumping and (2) inhibition of mitochondrial function (Lampidis et al. 1979) . As our data indicate that ICRF-1 87 will block the histological but not the functional effects of doxorubicin, it may be that ICRF-187 blocks the nuclear, but not the mitochondrial, or energy-related, effects of this drug. Doxorubicin also reduces the calcium-exchangeable fraction in spontaneously beating isolated guinea-pig atria (Villani et al. (1978) . Possibly this is the effect of doxorubicin which relates to reduced histamine responsiveness of the atria and is not blocked by ICRF-187. noted that ICRF-187 was not effective in blocking all toxic responses to doxorubicin. Specifically, while effective against myocardial histological damage, pretreatment with ICRF-187 did not influence doxorubicininduced bone-marrow depression or alopecia in dogs. Also, in the present studies, ICRF-187 did not prevent the adverse effects of doxorubicin on growth. Thus, in addition to not having uniform anti-doxorubicin toxocity activity in all tissues, the data suggest that ICRF-187 may not be specific for all the cardiac effects of doxorubicin. Pretreatment with ICRF-187 reduced myocardial histological damage in the mouse, but did not block the functional effect of doxorubicin on atrial responsiveness to histamine in the guinea pig.
